Abstract | BACKGROUND: AIM: METHODS: RESULTS: The two groups of patients had similar clinical, endoscopic, and haematological characteristics. Control of bleeding was achieved in 18 out of 30 patients (60%) in group I and 26 out of 30 patients (87%) in group II (p<0.05). There was no significant difference in mean transfusion requirements between the two groups: 2.6 (2.2) v 1.8 (1.6) respectively; means (SD). Mortality and side effects were similar in the two groups, but development of ascites was higher in group I (30%) than in group II (7%) (p<0.05). CONCLUSION: In cirrhotic patients with acute gastro-oesophageal variceal bleeding, addition of isosorbide 5-mononitrate to somatostatin does not improve therapeutic efficacy, induces more adverse effects, and should not be used.
|
Authors | F Junquera, J C López-Talavera, F Mearin, E Saperas, S Videla, J R Armengol, R Esteban, J R Malagelada |
Journal | Gut
(Gut)
Vol. 46
Issue 1
Pg. 127-32
(Jan 2000)
ISSN: 0017-5749 [Print] England |
PMID | 10601068
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Delayed-Action Preparations
- Vasodilator Agents
- Somatostatin
- Isosorbide Dinitrate
- isosorbide-5-mononitrate
|
Topics |
- Acute Disease
- Aged
- Delayed-Action Preparations
(therapeutic use)
- Double-Blind Method
- Drug Therapy, Combination
- Esophageal and Gastric Varices
(drug therapy)
- Female
- Follow-Up Studies
- Gastrointestinal Hemorrhage
(drug therapy)
- Humans
- Isosorbide Dinitrate
(analogs & derivatives, therapeutic use)
- Male
- Middle Aged
- Somatostatin
(therapeutic use)
- Vasodilator Agents
(therapeutic use)
|